Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,006 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. Pacer Advisors Inc.’s holdings in Halozyme Therapeutics were worth $1,387,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Congress Asset Management Co. grew its holdings in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after acquiring an additional 251,711 shares during the period. Boston Trust Walden Corp grew its holdings in shares of Halozyme Therapeutics by 54.0% during the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after purchasing an additional 239,321 shares during the last quarter. South Street Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter worth $9,812,000. Finally, Hantz Financial Services Inc. acquired a new stake in Halozyme Therapeutics in the third quarter worth $9,260,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $56.64 on Monday. The business has a 50-day simple moving average of $50.65 and a two-hundred day simple moving average of $54.32. The stock has a market cap of $7.21 billion, a price-to-earnings ratio of 18.76, a PEG ratio of 0.42 and a beta of 1.24. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. JMP Securities raised their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.